<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36154436</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8395</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Expert review of vaccines</Title><ISOAbbreviation>Expert Rev Vaccines</ISOAbbreviation></Journal><ArticleTitle>Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.</ArticleTitle><Pagination><StartPage>1667</StartPage><EndPage>1674</EndPage><MedlinePgn>1667-1674</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14760584.2022.2128108</ELocationID><Abstract><AbstractText Label="BACKGROUND">Multiple vaccine options are available for polio prevention and risk management. Integrated global risk, economic, and poliovirus transmission modeling provides a tool to explore the dynamics of ending all use of one or more poliovirus vaccines to simplify the polio eradication endgame.</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS">With global reported cases of poliomyelitis trending higher since 2016, we apply an integrated global model to simulate prospective vaccine policies and strategies for OPV-using countries starting with initial conditions that correspond to the epidemiological poliovirus transmission situation at the beginning of 2022.</AbstractText><AbstractText Label="RESULTS">Abruptly ending all OPV use in 2023 and relying only on IPV to prevent paralysis with current routine immunization coverage would lead to expected reestablished endemic transmission of poliovirus types 1 and 2, and approximately 150,000 expected cases of poliomyelitis per year. Alternatively, if OPV-using countries restart trivalent OPV (tOPV) use for all immunization activities and end IPV use, the model shows the lowest anticipated annual polio cases and lowest costs.</AbstractText><AbstractText Label="CONCLUSIONS">Poor global risk management and coordination of OPV cessation remain a critical failure mode for the polio endgame, and national and global decision makers face difficult choices due to multiple available polio vaccine options and immunization strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-0849-9147</Identifier><AffiliationInfo><Affiliation>Kid Risk, Inc, Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalkowska</LastName><ForeName>Dominika A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc, Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badizadegan</LastName><ForeName>Kamran</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4900-9455</Identifier><AffiliationInfo><Affiliation>Kid Risk, Inc, Orlando, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NU2RGH001915</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NU2RGH001915</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Vaccines</MedlineTA><NlmUniqueID>101155475</NlmUniqueID><ISSNLinking>1476-0584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dynamic modeling</Keyword><Keyword MajorTopicYN="N">eradication</Keyword><Keyword MajorTopicYN="N">health economic analysis</Keyword><Keyword MajorTopicYN="N">interdependent risks</Keyword><Keyword MajorTopicYN="N">polio</Keyword><Keyword MajorTopicYN="N">poliovirus vaccine</Keyword></KeywordList><CoiStatement>Declaration of interest. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>26</Day><Hour>14</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36154436</ArticleId><ArticleId IdType="mid">NIHMS1891548</ArticleId><ArticleId IdType="pmc">PMC10116513</ArticleId><ArticleId IdType="doi">10.1080/14760584.2022.2128108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: Part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions. Expert Rev Vaccines. 2021. Apr;20(4):465–481.</Citation><ArticleIdList><ArticleId IdType="pubmed">33624568</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Med J Med. 2008;10(8):190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562150</ArticleId><ArticleId IdType="pubmed">18924642</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. 14th Meeting of the Global Commission for Certification of Poliomyelitis Eradication (GCC), Bali, Indonesia, 20–21
September, 2015. 
Summary of findings, decisions and recommendations 2015 [cited
2021 Jul 22]. Available from: http://polioeradication.org/wp-content/uploads/2016/07/1Report.pdf</Citation></Reference><Reference><Citation>World Health Organization. Report from the Twentieth Meeting of the Global Commission for Certification of Poliomyelitis Eradication, Geneva, Switzerland, 17–18
October
2019. 
2019 [cited
2019 Dec 31]. Available from: http://polioeradication.org/wp-content/uploads/2016/07/20th-meeting-of-the-Global-Commission-for-the-Certification-of-Eradication-of-Poliomyelitis-17-18-October-2019.pdf</Citation></Reference><Reference><Citation>World Health Organization. Wild poliovirus list: List of wild poliovirus by country and year
2022.  [cited
2022 23 Aug]. Available from: https://polioeradication.org/wp-content/uploads/2022/08/weekly-polio-analyses-WPV-20220823.pdf</Citation></Reference><Reference><Citation>Badizadegan K, Kalkowska DA, Thompson KM. Polio by the numbers - A global perspective. J Infect Dis. 2022. Apr 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556648</ArticleId><ArticleId IdType="pubmed">35415741</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. Am J Epidemiol. 2005. August;162(4):358–372.</Citation><ArticleIdList><ArticleId IdType="pubmed">16014773</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544–605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896540</ArticleId><ArticleId IdType="pubmed">22804479</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471–1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184393</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epi. 2010. Dec 1;172(11):1213–1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2991634</ArticleId><ArticleId IdType="pubmed">20978089</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296(5566):356–359.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896235</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, et al. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703–749.</Citation><ArticleIdList><ArticleId IdType="pubmed">23521018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Sutter RW, De Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann Rev Microbiol. 2005;59(1):587–635.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Classification and reporting of vaccine-derived polioviruses (VDPV). 2015. 
August. Available from: https://polioeradication.org/wp-content/uploads/2016/09/Reporting-and-Classification-of-VDPVs_Aug2016_EN.pdf</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Standard operating procedures - Responding to a poliovirus event or outbreak - version 4 2022 [cited
2022 20 Aug]. Available from: https://polioeradication.org/wp-content/uploads/2022/07/Standard-Operating-Procedures-For-Responding-to-a-Poliovirus-Event-Or-Outbreak-20220807-EN-Final.pdf</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infectious Diseases. 2015;15(379):doi:10.1186/s12879-015-1115-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1115-5</ArticleId><ArticleId IdType="pmc">PMC4574619</ArticleId><ArticleId IdType="pubmed">26382043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Thompson KM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiology and Infection. 2019;147:e295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813650</ArticleId><ArticleId IdType="pubmed">31647050</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassalik SGF, et al. An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infect Dis. 2015;15(389):doi:10.1186/s12879-015-1112-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1112-8</ArticleId><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wassilak SGF, Cochi SL, et al. Global transmission of live polioviruses: Updated integrated dynamic modeling of the polio endgame. Risk Anal. 2021;41(2):248–265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787008</ArticleId><ArticleId IdType="pubmed">31960533</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Pallansch MA, Duintjer Tebbens RJ, et al. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 2013;33(4):647–663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896539</ArticleId><ArticleId IdType="pubmed">22985171</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of live polioviruses Vaccine. 2015. March 24;33(3):1568–1577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7907970</ArticleId><ArticleId IdType="pubmed">25701673</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowdle WR, de Gourville E, Kew OM, et al. Polio eradication: the OPV paradox. Rev Med Virol. 2003. Sep–Oct;13(5):277–91.</Citation><ArticleIdList><ArticleId IdType="pubmed">12931339</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1), WHO, Geneva, 19–24
May
2008. 
Geneva: World Health Organization; 2008 [cited
2019 Jun 4]. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf</Citation></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - Worldwide, 2016. MMWR. 2016. September 9;65(35):934–938.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM. Polio eradication: what kind of world do we want? Lancet Infect Dis. 2022. Oct 11;22(2):161–163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8504921</ArticleId><ArticleId IdType="pubmed">34648732</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus
2022.  [cited
2022 16 August]. Available from: https://polioeradication.org/wp-content/uploads/2022/08/weekly-polio-analyses-cVDPV-20220816.pdf</Citation></Reference><Reference><Citation>Macklin G, Peak C, Eisenhawer M, et al. Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience. Vaccine. 2022. Mar 17; S0264–410X(22)00195–5. doi: 10.1016/j.vaccine.2022.02.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.050</ArticleId><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Cochi SL, et al. Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart. Risk Anal. 2021;41(2):320–328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7814395</ArticleId><ArticleId IdType="pubmed">32632925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wilkinson A, et al. Updated characterization of poliovirus outbreak response strategies for 2019–2029: Impacts of the use of novel OPV2 strains. Risk Anal. 2021;41(2):329–348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887065</ArticleId><ArticleId IdType="pubmed">33174263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wassilak SGF, et al. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response Vaccine. 2021. May 13:doi: 10.1016/j.vaccine.2021.04.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.061</ArticleId><ArticleId IdType="pmc">PMC11027208</ArticleId><ArticleId IdType="pubmed">33994237</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet. 2007. Apr 21;369(9570):1363–71.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448822</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita I, Nakane M, Fenner F. Public health. Is polio eradication realistic? Science. 2006. May 12;312(5775):852–854.</Citation><ArticleIdList><ArticleId IdType="pubmed">16690846</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Poliomyelitis vaccination coverage
2022.  [cited
2022 17 May]. Available from: https://immunizationdata.who.int/pages/coverage/pol.html</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Polio eradication strategy 2022–2026: Delivering on a promise
2021.  [cited
2021 Jun 11]. Available from: https://polioeradication.org/wp-content/uploads/2021/06/polio-eradication-strategy-2022-2026-pre-publication-version-20210609.pdf</Citation></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ, Pallansch MA, et al. Polio eradicators use integrated analytical models to make better decisions. Interfaces. 2015. January–February;45(1):5–25.</Citation></Reference><Reference><Citation>Thompson KM, Kalkowska DA. An updated economic analysis of the Global Polio Eradication Initiative. Risk Anal. 2021;41(2):393–406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894996</ArticleId><ArticleId IdType="pubmed">33590521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann M, Hagedorn B, Lyons H. Projection of costs of polio eradication compared to permanent control. Journal of Infectious Diseases. 2020. Sep 30;221(4):561–565.</Citation><ArticleIdList><ArticleId IdType="pubmed">31565733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Thompson KM. Health and economic outcomes associated with polio vaccine policy options: 2019–2029. Risk Anal. 2021;41(2):364–375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7895457</ArticleId><ArticleId IdType="pubmed">33590519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Badizadegan K, Thompson KM. Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan. Risk Anal. 2022:In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780402</ArticleId><ArticleId IdType="pubmed">35739080</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines. 2018. 2018/08/03;17(8):739–751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168953</ArticleId><ArticleId IdType="pubmed">30056767</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA. Potential future use, costs, and value of poliovirus vaccines. Risk Anal. 2021. Feb;41(2):349–363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7984393</ArticleId><ArticleId IdType="pubmed">32645244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Thompson KM. Expected implications of globally-coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV. Risk Anal. 2021;41(2):312–319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887090</ArticleId><ArticleId IdType="pubmed">32936466</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Economic analysis of the Global Polio Eradication Initiative. Vaccine. 2011. December 16;29(2):334–343.</Citation><ArticleIdList><ArticleId IdType="pubmed">21029809</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA. Reflections on modeling poliovirus transmission and the polio eradication endgame. Risk Anal. 2021. Feb;41(2):229–247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7983882</ArticleId><ArticleId IdType="pubmed">32339327</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Wallace GS, Duintjer Tebbens RJ, et al. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Reports. 2012;127(1):23–37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234395</ArticleId><ArticleId IdType="pubmed">22298920</ArticleId></ArticleIdList></Reference><Reference><Citation>Anis E, Kopel E, Singer S, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveillance. 2013;18(38):20586.</Citation><ArticleIdList><ArticleId IdType="pubmed">24084337</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachlin A, Patel JC, Burns CC, et al. Progress toward polio eradication - worldwide, January 2020-April 2022. MMWR Morb Mortal Wkly Rep. 2022. May 13;71(19):650–655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098249</ArticleId><ArticleId IdType="pubmed">35552352</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K, Ehrenfeld E, Agol VI, et al. Polio eradication at the crossroads. The Lancet Global Health. 2021;9(8):E1172–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34118192</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsian J, Fox H, Bahar MW, et al. Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine. Nat Commun. 2017. Aug 15;8(1):245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557999</ArticleId><ArticleId IdType="pubmed">28811473</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry L, Grehan K, Snowden JS, et al. Comparative molecular biology approaches for the production of poliovirus virus-like particles using Pichia pastoris. mSphere. 2020. Mar 11;5(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067596</ArticleId><ArticleId IdType="pubmed">32161150</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Ma S, Huang Y, et al. Virus-like particle vaccines for poliovirus types 1, 2, and 3 with enhanced thermostability expressed in insect cells. Vaccine. 2019. Apr 17;37(17):2340–2347.</Citation><ArticleIdList><ArticleId IdType="pubmed">30922699</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahar MW, Porta C, Fox H, et al. Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. NPJ Vaccines. 2021. Jan 8;6(1):5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7794334</ArticleId><ArticleId IdType="pubmed">33420068</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000–2019 to support global polio eradication. Expert Rev Vaccines. 2020;19(7):661–686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497282</ArticleId><ArticleId IdType="pubmed">32741232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Cochi SL, et al. Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response options. J Infect Dis. 2021. Apr 22;224(9):1529–1538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083227</ArticleId><ArticleId IdType="pubmed">33885734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Voorman A, Pallansch MA, et al. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine. 2021. Apr 27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10045205</ArticleId><ArticleId IdType="pubmed">33962838</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. nOPV2: Clinical development summary updated June 2022
2022.  [11 Aug 2022]. Available from: https://polioeradication.org/wp-content/uploads/2022/06/nOPV2-Clinical-Development-Summary_June-2022-Update_Final-EN.pdf</Citation></Reference><Reference><Citation>World Health Organization. Vaccine-derived poliovirus type 2 (VDPV2) detected in environmental samples in London, UK
2022.  [cited
2022 Jul 11]. Available from: https://polioeradication.org/wp-content/uploads/2021/12/weekly-polio-analyses-WPV-20211228.pdf</Citation></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Grotto I, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015;211(11):1800–1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887763</ArticleId><ArticleId IdType="pubmed">25505296</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Investment case 2022–2026. Geneva, Switzerland: World Health Organization; 2022. Available from: https://polioeradication.org/wp-content/uploads/2022/04/GPEI-Investment-Case-2022-2026-Web-EN.pdf</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>